Displaying drugs 11576 - 11600 of 11790 in total
Myrcludex B
Myrcludex B is under investigation in clinical trial NCT03546621 (A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D).
Investigational
Matched Description: … Myrcludex B is under investigation in clinical trial NCT03546621 (A Multicenter, Open-label, Randomized …
mRNA-3927
mRNA-3927 is an investigational mRNA therapy that consists of two mRNAs that encode for the alpha and beta subunits of the mitochondrial enzyme propionyl-CoA carboxylase (PCC) encapsulated within a lipid nanoparticle (LNP). Developed by Moderna Inc., it is being investigated for the treatment of propionic acidemia.
Investigational
Matched Description: … alpha and beta subunits of the mitochondrial enzyme propionyl-CoA carboxylase (PCC) encapsulated within a …
SO-101
SO-101(Silenor) is a low-dose oral tablet formulation of doxepin hydrochloride that is patent protected for its use in insomnia. Doxepin has been prescribed for more than 40 years for the treatment of depression and anxiety at dosages typically ranging from 75 mg to 300 mg per day.
Investigational
Matched Description: … SO-101(Silenor) is a low-dose oral tablet formulation of doxepin hydrochloride that is patent protected …
Liposomal prostaglandin E1
Liposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent. The liposomal formulation of PGE-1 changes the drug’s dynamics and improve its therapeutic index in ways that PGE-1 alone could not achieve.
Investigational
Matched Description: … Liposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet …
TD-2749
TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome (C-IBS), opioid-induced constipation, functional dyspepsia and diabetic gastroparesis.
Investigational
Matched Description: … selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a …
Posizolid
Posizolid (AZD2563) is an oxazolidinone antibiotic. In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial results (though no results were reported).
Investigational
Varespladib methyl
Varespladib methyl has been investigated for the treatment of Acute Coronary Syndrome. Studies showed that Varespladib methyl treatment resulted in significant positive changes on lipoproteins and inflammation.
Investigational
Fasinumab
Fasinumab is a human IgG1k monoclonal antibody targeted against nerve growth factor (NGF). It is currently under investigation for the treatment osteoarthritic pain and has demonstrated significantly greater pain relief and functional improvement as compared to standard therapy (i.e. NSAIDs and/or opioids) in this patient population. NGF was first discovered...
Investigational
Matched Description: … Fasinumab is a human IgG1k monoclonal antibody targeted against nerve growth factor (NGF). …
Motavizumab
Investigational
LS11
LS11(talaporfin sodium) is an agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity. After intratumoral activation by light emitting diodes, taporfin sodium forms an extended high energy conformational state that generates singlet oxygen, resulting in free radical-mediated cell death. It is used to treat many...
Investigational
Encenicline
Encenicline has been investigated for the treatment of Cognition, Schizophrenia, Alzheimer's Disease, Cardiac Repolarization, and Central Nervous System Diseases.
Investigational
GSK159797
GSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory disease such as asthma and COPD.
Investigational
IMC-1C11
IMC-1C11 is an anti-angiogenesis agent. It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation. IMC-1C11 is used for treatment of patients with liver metastases from colorectal carcinoma.
Investigational
Matched Description: … It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction …
Renzapride
Renzapride is currently in Phase III clinical development in the United States for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It has been suggested that renzapride is effective in the treatment of irritable bowel syndrome with alternating stool pattern. It is being developed by Alizyme of the UK.
Investigational
FX06
FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells. FX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development. It is being developed by Fibrex Medical Inc.
Investigational
Matched Description: … FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). …
ZEN-012
ZEN-012 is a novel small molecule and the first anti-cancer drug in development involving two mechanisms of action: tubulin and topoisomerase II inhibition. ZEN-012 also expresses additional modes of action such as pro-apoptotic and anti-angiogenic properties. It is developed for the treatment of solid tumors.
Investigational
Matched Description: … ZEN-012 is a novel small molecule and the first anti-cancer drug in development involving two mechanisms …
4-Phenylfentanyl
4-Phenylfentanyl is a sythetic opioid derived from fentanyl. 4-Phenylfentanyl is around 8x the potency of fentanyl in analgesic tests on animals, but more complex 4-heteroaryl derivatives such as substituted thiophenes and thiazoles are more potent still, as they are closer bioisosteres to the 4-carbomethoxy group of carfentanil.
Illicit
Matched Description: … 4-Phenylfentanyl is a sythetic opioid derived from fentanyl. 4-Phenylfentanyl is around 8x the potency …
Mequitazine
Mequitazine is a histamine H1 antagonist (antihistamine). It competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory...
Experimental
Matched Description: … Mequitazine is a histamine H1 antagonist (antihistamine). …
MF101
MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation. MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal...
Investigational
Matched Description: … MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone …
L523S
According to Nemunaitis J., et al, "L523S is an immunogenic lung cancer antigen that has demonstrated preclinical safety when the gene is injected intramuscularly as an expressive plasmid (pVAX/L523S) and when delivered following incorporation into an E1B-deleted adenovirus (Ad/L523S)." It has been investigated as a lung cancer vaccine.
Investigational
Matched Description: … [A175909] It has been investigated as a lung cancer vaccine. …
Clocapramine
Clocapramine is an atypical antipsychotic of the imidobenzyl class which was introduced in Japan in 1974 for the treatment of schizophrenia. In addition to psychosis, clocapramine has also been used to augment antidepressants in the treatment of anxiety and panic. Clocapramine has been implicated in at least one strange death,...
Experimental
Matched Description: … Clocapramine has been implicated in at least one strange death, including a suicide. …
Sonpiretigene isteparvovec
Sonpiretigene isteparvovec is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy. Developed by Nanoscope Therapeutics, it is being investigated for vision restoration in advanced retinitis pigmentosa (RP). Sonpiretigene isteparvovec consists of a fusion Adeno-associated virus (AAV) vector with three plasmids encoding opsins with spectrally-separated activation peaks.
Investigational
Matched Description: … [L46676] Sonpiretigene isteparvovec consists of a fusion Adeno-associated virus (AAV) vector with three …
Tipapkinogene sovacivec
Investigational
Ciglitazone
Developed by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class.
Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones. Several analogues were later developed, some of which—such as pioglitazone and troglitazone—made it to the market....
Experimental
Matched Description: … Ciglitazone is a potent and selective PPARγ ligand with an EC50 of 3.0 µM. ... Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones …
GFT14
GFT14 is a new class of medicaction for treatment of cardiometabolic disease. GFT14 aims to target mixed dyslipidemia of type IIb (high levels of triglycerides and LDL-C) as one of the major indications of cardiometabolic disease.
GFT14 is destined to improve the condition of patients at risk from cardiovascular disease...
Investigational
Matched Description: … GFT14 is a new class of medicaction for treatment of cardiometabolic disease. ... GFT14 is destined to improve the condition of patients at risk from cardiovascular disease by a simultaneous …
Displaying drugs 11576 - 11600 of 11790 in total